🏅 FDA Orphan Designation
Ogsiveo
nirogacestat
Manufacturer: SpringWorks Therapeutics (EMD Serono / Merck KGaA)
Indicated for:
Desmoid tumorOrphan
FDA-Approved Indications (1)
Desmoid tumorOrphan Designation
Adult patients with progressing desmoid tumors who require systemic treatment. First and only FDA-approved treatment for desmoid tumors. Approved based on the DeFi Phase 3 randomized placebo-controlle…
Indications & Usage
1 INDICATIONS AND USAGE OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. ( 1 )
💙 Support Programs
View all →Ogsiveo
SpringWorks Therapeutics (EMD Serono / Merck KGaA)
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.